Inhibrx
INBX

$17.60

7.25%

Market Cap: $255M

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

66.63% more ownership

Funds ownership: 0% [Q1] → 66.63% (+66.63%) [Q2]

44% more call options, than puts

Call options by funds: $2.23M | Put options by funds: $1.54M

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for INBX.

See Analyst Rankings

Financial journalist opinion

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024

Inhibrx (NASDAQ: INBX ) just reported results for the first quarter of 2024. Inhibrx reported earnings per share of -$1.44.

INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders, which will be held on May 24, 2024. As a result, shares of SpinCo common stock are expected to begin trading on a "when-issued" basis on Nasdaq on May 28, 2024 (rather than May 16, 2024), under the symbol "INXB" and under "Inhibrx Biosciences, Inc." When-issued trading of shares of SpinCo common stock will continue until the distribution of shares of SpinCo common stock in the Spin-Off occurs.

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m.

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Zacks Investment Research

Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates

Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.

Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates

See News Rankings